02 — Telomere attrition
Primary hallmark ("damage") according to López-Otín et al., Cell 2023 (doi:10.1016/j.cell.2022.11.001).
1. Definition
Progressive shortening and dysfunction of telomeres, the repeated sequences (TTAGGG) that protect the ends of chromosomes. In humans, most somatic cells express little or no telomerase (the enzyme that lengthens them): with each division, telomeres shorten. When they become too short or damaged, the cell perceives them as a DNA break and stops dividing (senescence) or dies (Blackburn 2015, doi:10.1126/science.aab3389; Rossiello 2022, doi:10.1038/s41556-022-00842-x).
In plain terms: telomeres are like the plastic tips of shoelaces. They shorten with each division; when the tip disappears, the lace (the chromosome) frays and the cell stops dividing.
2. Mechanisms and sources
- End-replication problem: DNA polymerase does not fully copy the end of a chromosome; each division costs a few dozen base pairs. Without telomerase, this is a "division clock" (Hayflick limit).
- Oxidative damage: the guanine-rich sequences of telomeres are very sensitive to oxidation, which accelerates shortening beyond cell division alone.
- Irreparable telomeric damage: the protective "shelterin" complex prevents repair of chromosome ends (to avoid chromosome fusions). The downside: a lesion inside a telomere, even a long one, is not repaired and sustains a persistent DNA damage response (DDR). These telomeric foci accumulate with age, including in tissues that do not divide (neurons, muscle), in mice and primates (Fumagalli 2012, doi:10.1038/ncb2466; Hewitt 2012, doi:10.1038/ncomms1708). The hallmark is therefore not reducible to "length".
- Cellular consequences: DDR → activation of p53/p21 → senescence or apoptosis. In mice without telomerase, p53 also represses PGC-1α/β, the master regulators of mitochondria: telomere dysfunction causes metabolic and mitochondrial dysfunction (Sahin 2011, doi:10.1038/nature09787).
- Heritability and determinants: telomere length at birth is largely genetic; several loci (including TERT, TERC, OBFC1) influence mean leukocyte telomere length (Codd 2013, doi:10.1038/ng.2528). Tobacco, obesity, chronic stress and inflammation are associated with shorter telomeres in observational studies, with modest effects and uncertain causality (Blackburn 2015).
- Mouse/human difference: laboratory mice have very long telomeres and active telomerase; several generations without telomerase are needed to see effects. Mouse models therefore exaggerate or distort the human phenomenon.
3. Symptoms and clinical manifestations
Telomere syndromes (telomeropathies) — human monogenic evidence: mutations in telomerase genes (TERT, TERC, DKC1, RTEL1…) cause "dyskeratosis congenita" and a spectrum of diseases: bone marrow failure (aplasia), idiopathic pulmonary fibrosis, cirrhosis, early greying, skin and nail abnormalities, increased cancer risk. Adult forms mainly present as pulmonary fibrosis; the age of onset falls from generation to generation (anticipation), because the transmitted telomeres are shorter and shorter (Armanios 2012, doi:10.1038/nrg3246).
Cohorts and meta-analyses:
- Leukocytes with short telomeres are associated with an increased risk of coronary heart disease (meta-analysis of 24 studies, ~43,000 people; relative risk ~1.5 between extreme thirds) (Haycock 2014, doi:10.1136/bmj.g4227).
- Mendelian randomisation (a method that uses genetic variants as a "natural trial"): genetically longer telomeres increase the risk of several cancers (melanoma, lung, glioma…) but decrease the risk of coronary heart disease, aortic aneurysm and some lung diseases (Telomeres Mendelian Randomization Collaboration 2017, doi:10.1001/jamaoncol.2016.5945).
Key point: short telomeres are an anti-cancer brake. Lengthening them could protect tissues but favour tumours. This is the central trade-off of the hallmark.
Associated diseases: pulmonary fibrosis, bone marrow aplasia, cardiovascular diseases, cirrhosis; cancers (through excess length or through chromosomal instability during a telomere crisis).
4. Interactions with the other hallmarks
| Hallmark (2023 numbering) | Link with telomere attrition |
|---|---|
| 1. Genomic instability | Dysfunctional telomeres are perceived as breaks; if they fuse, they trigger breakage-fusion-bridge cycles and chromosomal rearrangements. |
| 3. Epigenetic alterations | Telomeres are surrounded by heterochromatin; its loss with age weakens their protection. Subtelomeric regions change their methylation [to verify] (for humans). |
| 4. Loss of proteostasis | Indirect link through senescence (secretome, reticulum stress); poorly documented. |
| 6. Deregulated nutrient sensing | Telomeric stress interacts with mTOR and sirtuins (through p53 and NAD+); details still debated. |
| 7. Mitochondrial dysfunction | Telomeres → p53 → PGC-1 → mitochondria axis (Sahin 2011). |
| 8. Cellular senescence | Main historical trigger of replicative senescence (Hayflick limit). |
| 9. Stem cell exhaustion | Blood, lung and intestinal stem cells are the first affected in telomeropathies (aplasia, fibrosis). |
| 10. Altered intercellular communication | The secretome of senescent cells of telomeric origin alters neighbouring tissues. |
| 11. Chronic inflammation | Inflammation and oxidative stress accelerate shortening; telomeric DDR feeds inflammation (vicious circle). |
| 12. Dysbiosis | Link not established [to verify]. |
5. Existing or investigational remedies
| Intervention | Target | Level of evidence | Key result | Source |
|---|---|---|---|---|
| Danazol (synthetic androgen) | Increases TERT expression | Human phase 1-2 trial (telomeropathies) | In 12 evaluable patients out of 27 enrolled, telomere length gain in 11/12 at 24 months and haematological responses; liver and muscle toxicities | Townsley 2016, doi:10.1056/NEJMoa1515319 |
| TERT gene therapy (AAV9) | Lengthen telomeres | Preclinical (mice) | Injection in adult (1 year) and old (2 years) mice: +24 % and +13 % median lifespan, better health, no increase in cancers | Bernardes de Jesus 2012, doi:10.1002/emmm.201200245 |
| Telomerase reactivation (genetic model) | Restore telomerase | Preclinical (telomerase-deficient mice) | Reversal of tissue degeneration (testes, spleen, gut, brain) | Jaskelioff 2010, doi:10.1038/nature09603 |
| TA-65 (cycloastragenol, astragalus extract) | Presumed telomerase activator | Uncontrolled human study, funded by the manufacturer | Effects on immune markers; no robust evidence on health or longevity | Harley 2011, doi:10.1089/rej.2010.1085 |
| Bone marrow / lung transplantation | Replace the failing organ | Clinical practice (telomeropathies) | Treats the organ, not the telomere defect; increased toxicity of conditioning regimens | Armanios 2012 |
| Lifestyle (stopping smoking, physical activity, stress reduction) | Slow attrition | Observational | Modest associations; causality not proven | Blackburn 2015 |
Finding: no intervention has been shown in humans to improve health by lengthening telomeres outside telomeropathies. Mendelian randomisation suggests an increased cancer risk with longer telomeres (Telomeres MR Collaboration 2017).
6. Open questions
- Length or damage? Foci of telomeric DDR in tissues that do not divide (Hewitt 2012; Fumagalli 2012) suggest that mean length measured in blood is not the right indicator.
- Value of leukocyte length as a biomarker: high variability between individuals and between methods (qPCR vs Southern blot); weak individual predictive power.
- Cancer/degeneration trade-off: can telomerase be activated transiently or in a targeted way without increasing tumour risk? The reassuring mouse results (Bernardes de Jesus 2012) do not translate directly.
- Relevance in normal older humans: does telomere shortening contribute to aging outside telomeropathies, or only in certain organs (blood, lung)?
- Causality of lifestyle factors: do tobacco, stress and obesity really shorten telomeres, or are these confounders?
7. References
- López-Otín C, et al. Hallmarks of aging: an expanding universe. Cell 2023. doi:10.1016/j.cell.2022.11.001
- Blackburn EH, Epel ES, Lin J. Human telomere biology: a contributory and interactive factor in aging, disease risks, and protection. Science 2015. doi:10.1126/science.aab3389
- Rossiello F, et al. Telomere dysfunction in ageing and age-related diseases. Nat Cell Biol 2022. doi:10.1038/s41556-022-00842-x
- Fumagalli M, et al. Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. Nat Cell Biol 2012. doi:10.1038/ncb2466
- Hewitt G, et al. Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. Nat Commun 2012. doi:10.1038/ncomms1708
- Sahin E, et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011. doi:10.1038/nature09787
- Codd V, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet 2013. doi:10.1038/ng.2528
- Armanios M, Blackburn EH. The telomere syndromes. Nat Rev Genet 2012. doi:10.1038/nrg3246
- Haycock PC, et al. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. BMJ 2014. doi:10.1136/bmj.g4227
- Telomeres Mendelian Randomization Collaboration. Association between telomere length and risk of cancer and non-neoplastic diseases: a Mendelian randomization study. JAMA Oncol 2017. doi:10.1001/jamaoncol.2016.5945
- Townsley DM, et al. Danazol treatment for telomere diseases. NEJM 2016. doi:10.1056/NEJMoa1515319
- Bernardes de Jesus B, et al. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Mol Med 2012. doi:10.1002/emmm.201200245
- Jaskelioff M, et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 2010. doi:10.1038/nature09603
- Harley CB, et al. A natural product telomerase activator as part of a health maintenance program. Rejuvenation Res 2011. doi:10.1089/rej.2010.1085
DOIs verified via the Crossref API on 2026-10-19.